Compare PHUN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHUN | VTGN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 25.3M |
| IPO Year | 2016 | 2014 |
| Metric | PHUN | VTGN |
|---|---|---|
| Price | $2.06 | $0.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.25 | $0.90 |
| AVG Volume (30 Days) | 89.5K | ★ 2.9M |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | $89.86 | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $0.20 |
| 52 Week High | $3.13 | $5.14 |
| Indicator | PHUN | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 38.43 |
| Support Level | $2.00 | $0.21 |
| Resistance Level | $2.11 | $0.66 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 29.17 | 11.49 |
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services. Development services for customers who wish to have a customized application experience; and In-app advertising services for mobile audience building, user acquisition, application discovery, audience engagement and monetization.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.